LymphedemaV1, Pmc, Corpus, bibRecord, 000B61

The secretory proprotein convertases furin, PC5, and PC7 activate VEGF-C to induce tumorigenesis

Identifieur interne : 000B61 ( Pmc/Corpus ); précédent : 000B60; suivant : 000B62

The secretory proprotein convertases furin, PC5, and PC7 activate VEGF-C to induce tumorigenesis

Auteurs : Geraldine Siegfried ; Ajoy Basak ; James A. Cromlish ; Suzanne Benjannet ; Jadwiga Marcinkiewicz ; Michel Chrétien ; Nabil G. Seidah ; Abdel-Majid Khatib

Source :

Journal of Clinical Investigation [ 0021-9738 ] ; 2003.

RBID : PMC:156106

Abstract

The secretory factor VEGF-C has been directly implicated in various physiological processes during embryogenesis and human cancers. However, the importance of the conversion of its precursor proVEGF-C to mature VEGF-C in tumorigenesis, and vessel formation and the identity of the protease(s) that regulate these processes is/are not known. The intracellular processing of proVEGF-C that occurs within the dibasic motif HSIIRR²²⁷SL suggests the involvement of the proprotein convertases (PCs) in this process. In addition, furin and VEGF-C were found to be coordinately expressed in adult mouse tissues. Cotransfection of the furin-deficient colon carcinoma cell line LoVo with proVEGF-C and different PC members revealed that furin, PC5, and PC7 are candidate VEGF-C convertases. This finding is consistent with the in vitro digestions of an internally quenched synthetic fluorogenic peptide mimicking the cleavage site of proVEGF-C (²²⁰Q-VHSIIRR↓SLP²³⁰). The processing of proVEGF-C is blocked by the inhibitory prosegments of furin, PC5, and PACE4, as well as by furin-motif variants of α2-macroglobulin and α1-antitrypsin. Subcutaneous injection of CHO cells stably expressing VEGF-C into nude mice enhanced angiogenesis and lymphangiogenesis, but not tumor growth. In contrast, expression of proVEGF-C obtained following mutation of the cleavage site (HSIIRR²²⁷SL to HSIISS²²⁷SL) inhibits angiogenesis and lymphangiogenesis as well as tumor growth. Our findings demonstrate the processing of proVEGF-C by PCs and highlight the potential use of PC inhibitors as agents for inhibiting malignancies induced by VEGF-C.

Url:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC156106

DOI: 10.1172/JCI200317220
PubMed: 12782675
PubMed Central: 156106

Links to Exploration step

PMC:156106

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The secretory proprotein convertases furin, PC5, and PC7 activate VEGF-C to induce tumorigenesis</title>
<author><name sortKey="Siegfried, Geraldine" sort="Siegfried, Geraldine" uniqKey="Siegfried G" first="Geraldine" last="Siegfried">Geraldine Siegfried</name>
<affiliation><nlm:aff id="N0x9626200.0x9af66f8">Laboratory of Biochemical Neuroendocrinology, Clinical Research Institute of Montreal, Montreal, Quebec, Canada</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Basak, Ajoy" sort="Basak, Ajoy" uniqKey="Basak A" first="Ajoy" last="Basak">Ajoy Basak</name>
<affiliation><nlm:aff id="N0x9626200.0x9af66f8">Regional Protein Chemistry Centre, Diseases of Aging Program, Ottawa Health Research Institute, Ottawa, Ontario, Canada</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Cromlish, James A" sort="Cromlish, James A" uniqKey="Cromlish J" first="James A." last="Cromlish">James A. Cromlish</name>
<affiliation><nlm:aff id="N0x9626200.0x9af66f8">Laboratory of Biochemical Neuroendocrinology, Clinical Research Institute of Montreal, Montreal, Quebec, Canada</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Benjannet, Suzanne" sort="Benjannet, Suzanne" uniqKey="Benjannet S" first="Suzanne" last="Benjannet">Suzanne Benjannet</name>
<affiliation><nlm:aff id="N0x9626200.0x9af66f8">Laboratory of Biochemical Neuroendocrinology, Clinical Research Institute of Montreal, Montreal, Quebec, Canada</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Marcinkiewicz, Jadwiga" sort="Marcinkiewicz, Jadwiga" uniqKey="Marcinkiewicz J" first="Jadwiga" last="Marcinkiewicz">Jadwiga Marcinkiewicz</name>
<affiliation><nlm:aff id="N0x9626200.0x9af66f8">Laboratory of Biochemical Neuroendocrinology, Clinical Research Institute of Montreal, Montreal, Quebec, Canada</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Chretien, Michel" sort="Chretien, Michel" uniqKey="Chretien M" first="Michel" last="Chrétien">Michel Chrétien</name>
<affiliation><nlm:aff id="N0x9626200.0x9af66f8">Regional Protein Chemistry Centre, Diseases of Aging Program, Ottawa Health Research Institute, Ottawa, Ontario, Canada</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Seidah, Nabil G" sort="Seidah, Nabil G" uniqKey="Seidah N" first="Nabil G." last="Seidah">Nabil G. Seidah</name>
<affiliation><nlm:aff id="N0x9626200.0x9af66f8">Laboratory of Biochemical Neuroendocrinology, Clinical Research Institute of Montreal, Montreal, Quebec, Canada</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Khatib, Abdel Majid" sort="Khatib, Abdel Majid" uniqKey="Khatib A" first="Abdel-Majid" last="Khatib">Abdel-Majid Khatib</name>
<affiliation><nlm:aff id="N0x9626200.0x9af66f8">Regional Protein Chemistry Centre, Diseases of Aging Program, Ottawa Health Research Institute, Ottawa, Ontario, Canada</nlm:aff>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">12782675</idno>
<idno type="pmc">156106</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC156106</idno>
<idno type="RBID">PMC:156106</idno>
<idno type="doi">10.1172/JCI200317220</idno>
<date when="2003">2003</date>
<idno type="wicri:Area/Pmc/Corpus">000B61</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000B61</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">The secretory proprotein convertases furin, PC5, and PC7 activate VEGF-C to induce tumorigenesis</title>
<author><name sortKey="Siegfried, Geraldine" sort="Siegfried, Geraldine" uniqKey="Siegfried G" first="Geraldine" last="Siegfried">Geraldine Siegfried</name>
<affiliation><nlm:aff id="N0x9626200.0x9af66f8">Laboratory of Biochemical Neuroendocrinology, Clinical Research Institute of Montreal, Montreal, Quebec, Canada</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Basak, Ajoy" sort="Basak, Ajoy" uniqKey="Basak A" first="Ajoy" last="Basak">Ajoy Basak</name>
<affiliation><nlm:aff id="N0x9626200.0x9af66f8">Regional Protein Chemistry Centre, Diseases of Aging Program, Ottawa Health Research Institute, Ottawa, Ontario, Canada</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Cromlish, James A" sort="Cromlish, James A" uniqKey="Cromlish J" first="James A." last="Cromlish">James A. Cromlish</name>
<affiliation><nlm:aff id="N0x9626200.0x9af66f8">Laboratory of Biochemical Neuroendocrinology, Clinical Research Institute of Montreal, Montreal, Quebec, Canada</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Benjannet, Suzanne" sort="Benjannet, Suzanne" uniqKey="Benjannet S" first="Suzanne" last="Benjannet">Suzanne Benjannet</name>
<affiliation><nlm:aff id="N0x9626200.0x9af66f8">Laboratory of Biochemical Neuroendocrinology, Clinical Research Institute of Montreal, Montreal, Quebec, Canada</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Marcinkiewicz, Jadwiga" sort="Marcinkiewicz, Jadwiga" uniqKey="Marcinkiewicz J" first="Jadwiga" last="Marcinkiewicz">Jadwiga Marcinkiewicz</name>
<affiliation><nlm:aff id="N0x9626200.0x9af66f8">Laboratory of Biochemical Neuroendocrinology, Clinical Research Institute of Montreal, Montreal, Quebec, Canada</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Chretien, Michel" sort="Chretien, Michel" uniqKey="Chretien M" first="Michel" last="Chrétien">Michel Chrétien</name>
<affiliation><nlm:aff id="N0x9626200.0x9af66f8">Regional Protein Chemistry Centre, Diseases of Aging Program, Ottawa Health Research Institute, Ottawa, Ontario, Canada</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Seidah, Nabil G" sort="Seidah, Nabil G" uniqKey="Seidah N" first="Nabil G." last="Seidah">Nabil G. Seidah</name>
<affiliation><nlm:aff id="N0x9626200.0x9af66f8">Laboratory of Biochemical Neuroendocrinology, Clinical Research Institute of Montreal, Montreal, Quebec, Canada</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Khatib, Abdel Majid" sort="Khatib, Abdel Majid" uniqKey="Khatib A" first="Abdel-Majid" last="Khatib">Abdel-Majid Khatib</name>
<affiliation><nlm:aff id="N0x9626200.0x9af66f8">Regional Protein Chemistry Centre, Diseases of Aging Program, Ottawa Health Research Institute, Ottawa, Ontario, Canada</nlm:aff>
</affiliation>
</author>
</analytic>
<series><title level="j">Journal of Clinical Investigation</title>
<idno type="ISSN">0021-9738</idno>
<imprint><date when="2003">2003</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p>The secretory factor VEGF-C has been directly implicated in various physiological processes during embryogenesis and human cancers. However, the importance of the conversion of its precursor proVEGF-C to mature VEGF-C in tumorigenesis, and vessel formation and the identity of the protease(s) that regulate these processes is/are not known. The intracellular processing of proVEGF-C that occurs within the dibasic motif HSIIRR<sup>227</sup>
SL suggests the involvement of the proprotein convertases (PCs) in this process. In addition, furin and VEGF-C were found to be coordinately expressed in adult mouse tissues. Cotransfection of the furin-deficient colon carcinoma cell line LoVo with proVEGF-C and different PC members revealed that furin, PC5, and PC7 are candidate VEGF-C convertases. This finding is consistent with the in vitro digestions of an internally quenched synthetic fluorogenic peptide mimicking the cleavage site of proVEGF-C (<sup>220</sup>
Q-VHSIIRR↓SLP<sup>230</sup>
). The processing of proVEGF-C is blocked by the inhibitory prosegments of furin, PC5, and PACE4, as well as by furin-motif variants of α2-macroglobulin and α1-antitrypsin. Subcutaneous injection of CHO cells stably expressing VEGF-C into nude mice enhanced angiogenesis and lymphangiogenesis, but not tumor growth. In contrast, expression of proVEGF-C obtained following mutation of the cleavage site (HSIIRR<sup>227</sup>
SL to HSII<underline>SS</underline>
<sup>227</sup>
SL) inhibits angiogenesis and lymphangiogenesis as well as tumor growth. Our findings demonstrate the processing of proVEGF-C by PCs and highlight the potential use of PC inhibitors as agents for inhibiting malignancies induced by VEGF-C.</p>
</div>
</front>
</TEI>
<pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
  <front><journal-meta><journal-id journal-id-type="nlm-ta">J Clin Invest</journal-id>
<journal-id journal-id-type="publisher-id">J CLIN INVEST</journal-id>
<journal-title>Journal of Clinical Investigation</journal-title>
<issn pub-type="ppub">0021-9738</issn>
<publisher><publisher-name>American Society for Clinical Investigation</publisher-name>
</publisher>
</journal-meta>
<article-meta><article-id pub-id-type="pmid">12782675</article-id>
<article-id pub-id-type="pmc">156106</article-id>
<article-id pub-id-type="publisher-id">17220</article-id>
<article-id pub-id-type="doi">10.1172/JCI200317220</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Article</subject>
</subj-group>
</article-categories>
<title-group><article-title>The secretory proprotein convertases furin, PC5, and PC7 activate VEGF-C to induce tumorigenesis</article-title>
</title-group>
<contrib-group><contrib contrib-type="author"><name><surname>Siegfried</surname>
<given-names>Geraldine</given-names>
</name>
<xref ref-type="aff" rid="N0x9626200.0x9af66f8">1</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Basak</surname>
<given-names>Ajoy</given-names>
</name>
<xref ref-type="aff" rid="N0x9626200.0x9af66f8">2</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Cromlish</surname>
<given-names>James A.</given-names>
</name>
<xref ref-type="aff" rid="N0x9626200.0x9af66f8">1</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Benjannet</surname>
<given-names>Suzanne</given-names>
</name>
<xref ref-type="aff" rid="N0x9626200.0x9af66f8">1</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Marcinkiewicz</surname>
<given-names>Jadwiga</given-names>
</name>
<xref ref-type="aff" rid="N0x9626200.0x9af66f8">1</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Chrétien</surname>
<given-names>Michel</given-names>
</name>
<xref ref-type="aff" rid="N0x9626200.0x9af66f8">2</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Seidah</surname>
<given-names>Nabil G.</given-names>
</name>
<xref ref-type="aff" rid="N0x9626200.0x9af66f8">1</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Khatib</surname>
<given-names>Abdel-Majid</given-names>
</name>
<xref ref-type="aff" rid="N0x9626200.0x9af66f8">2</xref>
</contrib>
</contrib-group>
<aff id="N0x9626200.0x9af66f8"><label>1</label>
Laboratory of Biochemical Neuroendocrinology, Clinical Research Institute of Montreal, Montreal, Quebec, Canada<label>2</label>
Regional Protein Chemistry Centre, Diseases of Aging Program, Ottawa Health Research Institute, Ottawa, Ontario, Canada</aff>
<author-notes><fn><p>Address correspondence to: Abdel-Majid Khatib, Regional Protein Chemistry Centre, Diseases of Ageing Unit, Ottawa Health Research Institute, Loeb Building, 725 Parkdale Avenue, Ottawa, Ontario K1Y 4E9, Canada. Phone: (613) 798-5555 ext. 16086; Fax: (613) 761-4355; E-mail: <email>mkhatib@ohri.ca</email>
.</p>
</fn>
</author-notes>
<pub-date pub-type="ppub"><day>1</day>
<month>6</month>
<year>2003</year>
</pub-date>
<volume>111</volume>
<issue>11</issue>
<fpage>1723</fpage>
<lpage>1732</lpage>
<history><date date-type="received"><day>22</day>
<month>10</month>
<year>2002</year>
</date>
<date date-type="accepted"><day>19</day>
<month>3</month>
<year>2003</year>
</date>
</history>
<copyright-statement>Copyright © 2003, American Society for Clinical Investigation</copyright-statement>
<copyright-year>2003</copyright-year>
<abstract><p>The secretory factor VEGF-C has been directly implicated in various physiological processes during embryogenesis and human cancers. However, the importance of the conversion of its precursor proVEGF-C to mature VEGF-C in tumorigenesis, and vessel formation and the identity of the protease(s) that regulate these processes is/are not known. The intracellular processing of proVEGF-C that occurs within the dibasic motif HSIIRR<sup>227</sup>
SL suggests the involvement of the proprotein convertases (PCs) in this process. In addition, furin and VEGF-C were found to be coordinately expressed in adult mouse tissues. Cotransfection of the furin-deficient colon carcinoma cell line LoVo with proVEGF-C and different PC members revealed that furin, PC5, and PC7 are candidate VEGF-C convertases. This finding is consistent with the in vitro digestions of an internally quenched synthetic fluorogenic peptide mimicking the cleavage site of proVEGF-C (<sup>220</sup>
Q-VHSIIRR↓SLP<sup>230</sup>
). The processing of proVEGF-C is blocked by the inhibitory prosegments of furin, PC5, and PACE4, as well as by furin-motif variants of α2-macroglobulin and α1-antitrypsin. Subcutaneous injection of CHO cells stably expressing VEGF-C into nude mice enhanced angiogenesis and lymphangiogenesis, but not tumor growth. In contrast, expression of proVEGF-C obtained following mutation of the cleavage site (HSIIRR<sup>227</sup>
SL to HSII<underline>SS</underline>
<sup>227</sup>
SL) inhibits angiogenesis and lymphangiogenesis as well as tumor growth. Our findings demonstrate the processing of proVEGF-C by PCs and highlight the potential use of PC inhibitors as agents for inhibiting malignancies induced by VEGF-C.</p>
</abstract>
</article-meta>
</front>
</pmc>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Pmc/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B61 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000B61 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    LymphedemaV1
   |flux=    Pmc
   |étape=   Corpus
   |type=    RBID
   |clé=     PMC:156106
   |texte=   The secretory proprotein convertases furin, PC5, and PC7 activate VEGF-C to induce tumorigenesis
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i   -Sk "pubmed:12782675" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a LymphedemaV1

This area was generated with Dilib version V0.6.31.
Data generation: Sat Nov 4 17:40:35 2017. Site generation: Tue Feb 13 16:42:16 2024

	Serveur d'exploration sur le lymphœdème
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur le lymphœdème

The secretory proprotein convertases furin, PC5, and PC7 activate VEGF-C to induce tumorigenesis

The secretory proprotein convertases furin, PC5, and PC7 activate VEGF-C to induce tumorigenesis

Source :

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki